-
Even if the weight is normal, the body fat index is also related to the risk of cancer
Time of Update: 2021-03-26
The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
-
CStone Pharmaceuticals announces that China’s first selective RET inhibitor Pugeta® (Platinib Capsules) has been approved, providing new treatment options for lung cancer patients
Time of Update: 2021-03-26
(Platinib Capsules) As a national first-class new drug, it is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients who have previously received platinum-containing chemotherapy for transfection rearrangement (RET) gene fusion positive treatment.
-
Br J Cancer: PI3K signaling pathway activation leads to eribulin resistance in HER2-negative breast cancer
Time of Update: 2021-03-26
Researchers evaluated the drug resistance of eribulin in the HER2-BC cell line and patient-derived xenografts, and studied its correlation with mutations in the PI3K/AKT signaling pathway.
-
FDA approves pembrolizumab as the first-line treatment indication for esophageal cancer; China's first RET inhibitor, pratinib, is approved|Tumor News
Time of Update: 2021-03-26
(If you need the original text of the literature, you can add the editor's WeChat yxj_oncology to obtain) Key points: JCO: Tipifarnib has a significant effect on HRAS-mutated head and neck squamous cell carcinoma GUT: endoscopic radiofrequency ablation ± endoscopic resection has significant long-term effect on esophageal Barrett disease Neoadjuvant therapy with nizumab combined with high-dose interferon Alfa-2b is effective for resectable locally advanced melanoma.
-
The first domestic RET inhibitor! CStone's Pratinib approved
Time of Update: 2021-03-26
According to the announcement by the National Medical Products Administration (NMPA) on March 23, CStone’s RET inhibitor pralsetinib’s new drug listing application review and approval status has been updated to "Approval completed-pending certification", and the indication is Have previously received platinum-containing chemotherapy for transfection rearrangement (RET) fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
-
How can scientists help effectively fight cancer by stimulating the host's immune system?
Time of Update: 2021-03-26
Recently, in a research report entitled "Cell-Based Identification of New IDO1 Modulator Chemotypes" published in the international journal Angewandte Chemie International Edition , scientists from the Max Planck Society in Germany and other institutions developed a new type of A cell-based detection system to identify immunomodulatory mediators.
-
J Immunother Cancer: Camrelizumab combined with apatinib in the treatment of advanced liver cancer
Time of Update: 2021-03-26
Immune checkpoint inhibitors in combination with anti angiogenesis generator is reasonable strategy to treat a variety of malignant tumors of immune vesselsThis study is a multi-cohort phase Ib/II trial to evaluate the effect of human PD-1 monoclonal antibody Camrelizumab combined with apatinib in the treatment of advanced PLC.
-
Gut: Can anti-hepatitis C virus treatment prevent liver cancer recurrence after liver cancer treatment?
Time of Update: 2021-03-26
Assess the risk of liver cancer recurrence in these patients after taking DAAData from 977 patients from 21 HCV-related cirrhosis and HCC studies were included.
The recurrence rate and death risk of patients in the DAA group were 20/100 person-years (95%CI 13.
-
Significantly prolong survival, first-line treatment of esophageal cancer has made an important breakthrough in the past 30 years
Time of Update: 2021-03-26
The press release pointed out that this is the first anti-PD-1 immune combination therapy approved by the FDA for the first-line treatment of this patient group, and represents a major breakthrough in the first-line treatment of esophageal cancer in the past 30 years.
-
Hypoxia thinking after three months of squatting
Time of Update: 2021-03-26
It is very necessary to study the molecular markers related to hypoxia in breast cancer.
Hypoxia-related DEG prognostic markers and risk characteristics construction Figure 4.
Identification of hypoxia-related differential expression candidate miRNAs and enrichment analysis Figure 5.
Identification of hypoxia Oxygen-related differential expression candidate miRNA 6.
-
JCO: The efficacy of nivolumab combined with ipilimumab in maintenance treatment of advanced small cell lung cancer
Time of Update: 2021-03-26
Further analysis showed that compared with placebo, there was a difference in the progression-free survival of patients in the nivouliu combined with ipilimumab treatment group (HR=0.
-
A new treatment plan for advanced renal cell carcinoma-lenvatinib combined with pembrolizumab
Time of Update: 2021-03-26
In a multinational phase 3 trial, patients with previously untreated advanced renal cell carcinoma were randomly divided into 3 groups and received lenvatinib + pembrolizumab (Len/Pem; lenvatinib daily, Pembrolizumab is administered intravenously every 3 weeks), lenvatinib + everolimus (Len/Eve; both drugs are administered daily) or sunitinib (treatment for 4 weeks, drug withdrawal for 2 weeks) treatment.
-
Br J Cancer: Mandard grade is high: it does not mean that esophageal adenocarcinoma does not respond to chemotherapy
Time of Update: 2021-03-26
Kaplan-Meier analysis of patients' relapse-free survival rateAll in all, the results of the study show that in patients with poor Mandard grade, complete lymph node response can significantly improve patient outcomes.
In patients with poor Mandard grade, complete lymph node response can significantly improve the patient's outcome.
-
Revealing cancer mutations may be expected to help develop new cancer detection technologies and individualized anti-cancer therapies
Time of Update: 2021-03-26
March 26, 2021 // - Recently, in a research report titled "The landscape of the heritable cancer genome" published in the international journal Cancer Research , scientists from the University of Edinburgh and other institutions said through research that, Revealing new cancer mutations may be expected to help enhance the diagnosis of cancer and the development of personalized anti-cancer therapies.
-
The latest advances in clinical research on the first-line treatment of advanced hepatocellular carcinoma with "Treprizumab + Bevacizumab" are released
Time of Update: 2021-03-26
Take Junshi Bio’s teriprizumab as an example, in the combination of teriprizumab and bevacizumab we released today In the Phase II clinical trial for the first-line treatment of advanced hepatocellular carcinoma, we are pleased to see very exciting data results, which show that innovative drugs with China’s independent intellectual property rights can bring international-level treatment options for liver cancer patients.
-
JCO: Lower dose, better efficacy-Tamoxifen benefits more women!
Time of Update: 2021-03-26
5 mg of tamoxifen, the reduction in breast density was equivalent to that of the standard dose of 20 mg, but with fewer side effects.
5 mg of tamoxifen, the reduction in breast density was equivalent to that of the standard dose of 20 mg, but with fewer side effects.
-
Eur J Cancer: Hormone replacement therapy increases the risk of breast cancer in BRCA mutation carriers over 45 years old by 3 times!
Time of Update: 2021-03-26
8)In summary, among BRCA1/BRCA2 mutation carriers, women over 45 years of age who use hormone replacement therapy short-term after salpingo-oophorectomy have a three-fold increase in breast cancer risk .
-
Br J Cancer: Even if the weight is normal, body fat indicators are also related to the risk of cancer
Time of Update: 2021-03-26
1038/s41416-020-01210-y">The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank .
-
The world's first first-line treatment of esophageal cancer PD-1 was born!
Time of Update: 2021-03-26
The results of the interim analysis of KEYNOTE-590 showed that in the first-line treatment of patients with locally advanced and metastatic esophageal cancer, pembrolizumab combined with chemotherapy compared with conventional chemotherapy has brought benefits to the entire population, significantly improved overall survival, and reduced The risk of death from disease is 27%, and the safety is controllable.
-
Harvard scientists discovered an anti-cancer target that can not only affect tumor cells and improve the immune microenvironment, but also improve the anti-cancer activity of immune cells 丨 scientific discovery
Time of Update: 2021-03-26
Specifically, not only has the anti-cancer activity of T cells increased, but also the ability of T cells whose Carm1 gene has been knocked out to enter tumors has also increased.
